STOCKS TELEGRAPH

Tag: PFE stock

  • The 3 Best Pharmacy Stocks for long-term Investment

    The 3 Best Pharmacy Stocks for long-term Investment

    The pharma industry has been a long-term investment opportunity for investors over the years.

    The global pharmaceutical industry is a massive market that continues to grow each year. It is estimated to be more than $1.2 trillion in sales annually. The COVID-19 pandemic has been a massive catalyst in pushing pharma firms to their limit. The majority of the companies have tried their luck in developing the coronavirus vaccine—with several being successful and others under clinical trials.

    For investors, the pharmacy stocks have the potential to reap solid long-term results—with a broader market. Especially, with the demand for vaccines high all over the world, the pharma stocks could be making big profits in the future. So, let’s have a look at the three best pharma stocks for long-term investment.

    Pfizer (PFE)

    Pfizer (PFE) has been the highlight of last year. The US-based pharma firm was the first—in collaboration with BioNTech—to develop the COVID-19 vaccine. Despite the vaccine news, the stock price hasn’t skyrocketed as it was expected. So, there is much upside considering the stock being backed by Pfizer’s vaccine and other top-line products.

    Recently, the company reported its fourth-quarter results, with earnings on the lower side as per the expectations. The Q4 2020 adjusted earnings were $0.42 per share, topping by 14% Year-over-Year but missing analysts’ estimate of $0.51 per share. While, the sales increased by 12% to $11.68 billion, missing projected sales of $12.01 billion.

    Mizuho Securities analyst Vamil Divan said that the company has multiple parts under movement, but the long-term seems strong with its core assets performing well. Pfizer has reportedly said that they are expecting $15 billion of vaccine sales this year. So far, the company has vaccine sales of around $154 million.

    With much happening, Pfizer (PFE) stock is still in the buy range.

    Bristol-Myers (BMY)

    Bristol Myers Squibb (BMY) is one of the leading pharmaceutical firms in biologics in several therapeutic areas, including cancer. The company is set to release its fourth-quarter results on Feb. 4, 2021.

    According to Forbes, the overall outcome is expected to be slightly on the lighter side as per the analysts’ estimate. The quarterly results are affected by a slow sales growth rate of Opdivo. However, the company should see an increase in overall demand due to a rise in hospital visits.

    The company has announced that it has obtained positive outcomes from the second pivotal Phase 3 trial for its novel, oral, POETYK PSO-2. Bristol is working on selective tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis—patients with moderate to severe disease. Almost 100 million people are suffering from psoriasis around the world. If the company goes on to successfully market its product, it would bring massive revenue in the longer run.

    Furthermore, Bristol Myers Squibb (BMY) has collaborated with The Rockefeller University for the rights to a Covid-19 therapy that combines two antibodies. The company stated that the vaccine variant of Rockefeller has delivered effective results against SARS-CoV-2. So, this deal could be another big plus for Bristol as we head forward.

    Anavex (AVXL)

    Anavex Life Sciences (AVXL) is a promising biopharma firm that has gained a lot of attention for its lead candidate of Alzheimer’s disease, Anavex 2-73 (A2-73). Recently, the company updated that it has completed 80enrollment for the Phase 2b/3 trials. While the remaining enrollment of 450 patients is anticipated in near-future.

    Over the past 12-months, AVXL shares have soared over 163%. As of Feb. 4, in pre-market trading, the stock is up by nearly 87% trading around $19.67. The bullish sentiment is pushed by the lead drug of Anavex.

    So far, the data shows that Anavex 2-73 is very effective against Alzheimer’s disease. According to World Health Organization, more than 50 million suffer from dementia—a type of Alzheimer—all over the world. And, around 10 million new cases arise each year.

    Being bullish on Anavex, Seeking Alpha’scontributor Lane Simonian stated that Anavex 2-73 has the best chance of long-term success among the rest of the drugs being studied by the company. So, Anavex (AVXL) is a stock to watch for long-term investment.

  • Early Morning Vibes: 4 Best Stocks To Buy Today

    Early Morning Vibes: 4 Best Stocks To Buy Today

    On December 15, the American stock indices closed in positive territory. The S&P 500 index rose 1.29% to 3695 points, the Dow Jones rose 1.13%, the NASDAQ rose 1.25%. The main positive driver was the optimistic expectations regarding the new package of fiscal support. Increased risk appetite allowed all 11 sectors to close in the green zone. The tech sector became one of the leaders of growth, adding 1.61%, the locomotive was the shares of Apple.
     

    Corporate Update
     

    According to media reports, Apple (AAPL: + 5%) plans to increase iPhone production by 30% YoY amid strong demand for the new iPhone 12 Pro models.

    Eli Lilly (LLY: + 6%) released strong forecasts for 2021 and announced a deal to buy Prevail Therapeutics (PRVL: + 82%) for $ 1 billion.
     

    China’s Baidu Corporation (BIDU: + 13.8%) is considering entering the electric vehicle market and is in talks with automakers.
     

    Today, world stock exchanges are showing mostly positive dynamics. Two potential drivers of growth are in the spotlight: progress in negotiations between US lawmakers on a new package of economic support and the outcome of the Fed meeting. Congressmen continue to actively discuss the bill on measures to help the economy. At the moment, it is most likely that a package of about $ 750 billion will be accepted. This option excludes the most controversial aspects that have hindered a compromise over the past six months. Lawmakers plan to vote this week, while also approving other spending items, including an extension of government funding.
     

    The Fed is expected to repeat the rhetoric of previous meetings, active actions of the regulator are unlikely, as well as changes in long-term forecasts for the rate. Jerome Powell will re-emphasize the importance of fiscal policy. Most likely, the parameters of the program for purchasing government bonds will not be changed, but this program itself can be extended, which will support optimism in the markets.

    Today Top Movers


    Niu Technologies (NIU) is up 0.79% at $29.41 in premarket trading on Wednesday. In spite of no news on the stock directly, a broader piece of news today has helped several stocks.
     

    Hexo Corp (HEXO) share price increased 2.75% at $1.12 in today’s early morning session following the release of its first quarter fiscal 2021 financial results.
     

    Marathon Patent Group Inc (MARA) is going up 5.80% in premarket session on Wednesday. Despite few business articles or no business news lately, this stock has drastically climbed in value.
     

    Tilray Inc (TLRY) share price gaining 20.97% at $9.52 in premarket trading today following Its merger news with Aphria.

    Top Upgrades & Downgrades

    Credit Suisse turned bullish on Galera Therapeutics Inc. (GRTX), upgrading the stock to “Outperform” and assigning a $15.0 price target, representing potential upside of 18.48%.
     

    Atlantica Sustainable Infrastructure plc (AY) has won the favor of Seaport Global’s equity research team. The firm upgraded the shares from Neutral to Buy and moved their price target to $38.0.
     

    Wells Fargo & Company (WFC) received an upgrade from analysts at Keefe, Bruyette & Woods, who also set their one-year price target on the stock to $36.0. They changed their rating on WFC to Outperform from Market Perform in a recently issued research note.
     

    Earlier Wednesday RBC Capital reduced its rating on Pfizer Inc. (PFE) stock to Sector Perform from Outperform and assigned the price target to $42.0.
     

    KeyBanc analysts reduced their investment ratings, saying in research reports covered by the media that its rating for Aptiv PLC (APTV) has been changed to Sector Weight from Overweight.

    Latest Insider Activity


    Chewy Inc. (CHWY) Director STAR JAMES A announced the sale of shares taking place on Dec 11 at $85.06 for some 30,000 shares. The total came to more than $2.55 million.
     

    CarGurus Inc. (CARG) General Counsel and Secretary Patton Kathleen Bender sold on Dec 14 a total 103,142 shares at $30.00 on average. The insider’s sale generated proceeds of almost $0.17 million.
     

    Elys Game Technology Corp. (ELYS) Vice President of Technology Pasquini Luca declared the purchase of shares taking place on Dec 14 at $3.15 for some 1,000 shares. The transaction amount was around $3150.0.
     

    Retractable Technologies Inc. (RVP) President and CEO SHAW THOMAS J bought on Dec 14 a total 14,076,660 shares at $12.85 on average. The purchase cost the insider an estimated $3,007.

    Earnings To Watch


    Top US earnings releases scheduled for today include Lennar Corporation (NYSE:LEN). It will announce its Nov 2020 financial results. The company is expected to report earnings of $2.37 per share from revenues of $6.65B in the three-month period.
     

    Analysts expect Qutoutiao Inc. (NASDAQ:QTT) to report a net income (adjusted) of -$0.09 per share, when the bank releases its quarterly results shortly. Revenue for the fiscal quarter ended Sep 2020 is predicted to come in at $174.89M.
     

    Herman Miller Inc. (MLHR), due to announce earnings after the market closes today, is expected to report earnings of $0.56 per share from revenues of $585.5M recently concluded three-month period.

  • Are The Current Prices Weighing On Pfizer And BioNTech, When To Buy These Stock?

    Are The Current Prices Weighing On Pfizer And BioNTech, When To Buy These Stock?

    Without significant reservations, the vaccine from Pfizer and BioNTech was approved for review by the FDA. All the basic parameters of the vaccine have been verified by the Commission that approved the application, including that it is 95 percent successful. Furthermore other significant aspects of the research were revealed. That the vaccine triggers defense at the first injection, however a course of two injections is necessary to get immunity. After the first treatment, it is 52 percent successful (with the minimum FDA requirements of 50 percent).

    Cases of severe side effects, such as paralysis of the facial nerve and swelling of the lymph node, occur, but within the normal vaccine initiation figures. There were also cases of COVID-19 after vaccination, but all of them fall within a period of up to two weeks after the injection, that is, before the immunity acquired was established. Neither the vaccine nor COVID-19 were associated with patient deaths (6 episodes in total). Both of them occurred in chronic disease subjects.

    During the analysis of the certification application, all such data will be checked again. In the coming weeks, a decision could be taken, but the market is betting it will be unambiguously positive. Pfizer and BioNTech shares have risen in recent sessions. Starting on Monday, the former rose by 3.74 percent in total while the later stock gained 2.34 percent. The rise comes in the midst of a report by a number of investment firms of target prices for these stocks.

    In our view, shares of both vaccine developers have now reached their equal amount. Pfizer has the potential to fall by at least 5 percent in the medium term and up to 15 percent with a likely correction in the indexes. At a drop to $40, and at a rapid breakout of this level-from $37 each, we suggest entering the company’s shares. BioNTech has a more substantial speculative overhang, with its shares being able to change by 20% even with a neutral external backdrop in the coming months.

    In Wednesday session, Pfizer stock dropped by -1.67% while that of BioNTech was down -4.14%.

  • Is Pfizer (PFE) Stock Is Better Than Of Moderna (MRNA)?

    Is Pfizer (PFE) Stock Is Better Than Of Moderna (MRNA)?

    In December, Pfizer Inc (PFE) won’t be able to produce up to half of the new vaccine. The organization acknowledged that it is facing logistics issues. Customers will receive just 50 million out of the previously expected 100 million doses. The production goal remains the same for the whole of next year as Pfizer plans to ship about 1 billion doses. Even the closest rival Moderna Inc (MRNA) is adjusting the sales targets. Thus, it has been announced that the company will ship 100-125 million doses in the first quarter of 2021. This brings into question the achievement of the target of 500 million doses for the year as a whole and suggests implicitly that capability issues remain. The obstacles to mass delivery of Pfizer and Moderna vaccines are similar as they must be transported and stored at temperatures no higher than -20 and -70 degrees Celsius, respectively.

    The market responded to this news ambiguously. In the last week, though Moderna shares increased about 20 percent, Pfizer shares rose just 8 percent. Once again, players prefer a more costly and less mass-produced, but more compact, vaccine. In part, this disparity in valuation can be explained by the fact that in the United States, the number of firms able to assist in the delivery of drugs multiplied. This involves meat producers with cooling systems and Uber, which has formally appealed to the authorities to allow taxi drivers the right to distribute the vaccine to hospitals and pharmacies in need. Pharmacy chains also volunteered to open vaccination points, and some are already included in the US state program.

    The unhealthy panic around the Moderna Inc (MRNA) stock is not justified in our view. The prices of their shares have increased 1.8 times in a month, while retaining unchanged distribution plans, and are now at least one third more expensive than their equilibrium value.

    Pfizer Inc (PFE), which is less reliant on its sales from vaccinations, is undervalued. In the coming months, the shares have a potential of up to 5 percent. We suggest buying them on a drawdown when the price hits $37 a share, anticipating a short-term correction in the market.

  • 49 Stocks Making Sharp Moves in Pre Market Session

    49 Stocks Making Sharp Moves in Pre Market Session

    BlackBerry Limited (BB) stock soared 21.29% to $8.49 in the pre-market trading following the announcement of its multi-year, global agreement with Amazon Web Services, Inc. (AWS). The most recent rating by TD Securities, on April 01, 2020, is a Hold.
    Gores Metropoulos Inc. (GMHI), a Shell Companies company, dropped about -3.71% at $16.37 in pre-market trading Wednesday.
    Carnival Corporation & Plc (NYSE: CCL) shares are trading up 2.48% at $20.65 at the time of writing. The firm recently reported Peter C. Anderson as a Section 16 Named Executive Officer. Company’s 52-week ranged between $7.80 to $51.94. Analysts have a consensus price target of $31.
    Guardion Health Sciences Inc. (GHSI) is up more than 2.11% at $0.3 in pre-market hours Wednesday December 02, 2020. The stock had jumped over 11.71% to $0.29 in the last trading session.
    Advaxis Inc. (ADXS) grew over 0.85% at $0.32 in pre-market trading today. The healthcare company recently announced closing of $9.2 million public offering.
    Before the trading started on December 02, 2020, RiceBran Technologies (RIBT) is down -5.56% to reach $0.68. It has been trading in a 52-week range of $0.37 to $2.43.
    Sundial Growers Inc. (SNDL) stock moved up 5.75 percent to $0.69 in the pre-market trading and the company recently announced elimination of senior secured second lien convertible notes.
    Kaixin Auto Holdings (KXIN) is up more than 4.55% at $7.35 in pre-market hours Wednesday December 02, 2020. The stock had jumped over 8.32% to $7.03 in the last trading session.
    Moleculin Biotech Inc. (MBRX) lost over -7.83% at $0.9125 in pre-market trading Wednesday December 02, 2020 after declaring that the US Food and Drug Administration (FDA) has approved its request for a “Rare Pediatric Disease” designation for its drug candidate WP1066.
    Jaguar Health Inc. (JAGX) stock plunged -5.83% to $0.4313 in the pre-market trading. The most recent rating by Rodman & Renshaw, on July 11, 2017, is a Buy.
    Auris Medical Holding Ltd. (EARS) stock plunged -17.97% to $4.29 in the pre-market trading after reporting positive efficacy data from testing AM-301 in vitro. The most recent rating by Euro Pacific Capital, on October 08, 2018, is a Buy.
    Before the trading started on December 02, 2020, Sunworks Inc. (SUNW) is up 9.88% to reach $4.67. It has been trading in a 52-week range of $0.29 to $8.50.
    China Automotive Systems Inc. (NASDAQ: CAAS) shares are trading down -4.95% at $8.25 at the time of writing after the firm declared that its shipped approximately 120,000 units from its portfolio of electric power steering products for use in Chinese electric vehicles during 2020. Company’s 52-week ranged between $1.42 to $10.50.
    Tilray Inc. (NASDAQ: TLRY) shares are trading up 1.61% at $8.2 at the time of writing. Company’s 52-week ranged between $2.43 to $22.95. Analysts have a consensus price target of $4.77.
    Ocugen Inc. (OCGN) lost over -8.87% at $0.3101 in pre-market trading Wednesday December 02, 2020. The company recently reported that leading independent proxy firms ISS and Glass Lewis recommended Ocugen stockholders vote “FOR” reverse stock split and authorized shares amendment proposals.
    AMC Entertainment Holdings Inc. (AMC) is up more than 2.41% at $4.25 in pre-market hours Wednesday December 02, 2020. The stock had dropped over -2.81% to $4.15 in the last trading session.
    Before the trading started on December 02, 2020, JetBlue Airways Corporation (JBLU) is down -4.67% to reach $14.7 following the declaration of its pricing of common stock offering. It has been trading in a 52-week range of $6.61 to $21.65.
    Before the trading started on December 02, 2020, Uxin Limited (UXIN) is down -3.65% to reach $1.32. It has been trading in a 52-week range of $0.72 to $3.10.
    Li Auto Inc. (NASDAQ: LI) shares are trading up 1.78% at $35.48 at the time of writing after announcing that the Company delivered 4,646 Li ONEs in November 2020. Company’s 52-week ranged between $14.31 to $47.70. Analysts have a consensus price target of $45.60.
    Aurora Cannabis Inc. (ACB) stock soared 3.59% to $10.1 in the pre-market trading. The most recent rating by Jefferies, on November 16, 2020, is an Underperform.
    Tantech Holdings Ltd (TANH), a Household & Personal Products company, dropped about -3.24% at $1.79 in pre-market trading Wednesday after reporting the launch by its subsidiary, Shangchi Automobile Co., Ltd., of its newest highly innovative driverless and autonomous street sweeper.
    Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) shares are trading down -5.52% at $1.37 at the time of writing. Company’s 52-week ranged between $0.91 to $9.78. Analysts have a consensus price target of $3.
    iBio Inc. (IBIO) is up more than 19.31% at $1.73 in pre-market hours Wednesday December 02, 2020 after revealing that it has entered into its first Statement of Work (“SoW”) under a Master Services Agreement with ATB Therapeutics to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming® System. The stock had dropped over -2.68% to $1.45 in the last trading session.
    Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) shares are trading up 2.09% at $23.42 at the time of writing. Company’s 52-week ranged between $7.03 to $59.78. Analysts have a consensus price target of $26.
    Moderna Inc. (MRNA) stock soared 6.09% to $149.6 in the pre-market trading. The biotechnology firm reported recently, that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The most recent rating by Wells Fargo, on November 23, 2020, is an Equal weight.
    Switchback Energy Acquisition Corporation (SBE) is down more than -4.16% at $28.13 in pre-market hours Wednesday December 02, 2020. The stock had dropped over -12.67% to $29.35 in the last trading session.
    Novavax Inc. (NVAX) grew over 4.84% at $129.44 in pre-market trading today after declaring COVID-19 vaccine clinical development progress.
    Before the trading started on December 02, 2020, Eastman Kodak Company (KODK) is up 3.88% to reach $7.5. It has been trading in a 52-week range of $1.50 to $60.00.
    ReneSola Ltd (SOL), a Solar company, dropped about -11.66% at $6.97 in pre-market trading Wednesday after releasing its third quarter 2020 financial results.
    Acasti Pharma Inc. (ACST) stock plunged -9.56% to $0.3301 in the pre-market trading. The most recent rating by Oppenheimer, on September 01, 2020, is a Perform.
    Pfizer Inc. (PFE) stock moved up 3.73 percent to $40.88 in the pre-market trading after the firm and BioNTech SE reporting that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2), against COVID-19.
    Gevo Inc. (NASDAQ: GEVO) shares are trading down -3.17% at $1.83 at the time of writing. Company’s 52-week ranged between $0.46 to $2.91.
    Fisker Inc. (FSR) is down more than -3.41% at $17.55 in pre-market hours Wednesday December 02, 2020. The company recently reported that that Henrik Fisker, chairman and chief executive officer of Fisker, will participate in the Credit Suisse Eighth Annual Virtual Industrials Conference. The stock had dropped over -6.24% to $18.17 in the last trading session.
    Nxt-ID Inc. (NXTD) grew over 43.17% at $0.587 in pre-market trading today.
    Before the trading started on December 02, 2020, Bloom Energy Corporation (BE) is down -6.58% to reach $23.0 and the company will host virtual analyst day on December 16, 2020. It has been trading in a 52-week range of $3.00 to $28.24.
    Ocean Power Technologies Inc. (OPTT), a Electrical Equipment & Parts company, dropped about -3.54% at $2.45 in pre-market trading Wednesday.
    Nikola Corporation (NKLA) stock soared 4.38% to $18.13 in the pre-market trading after signing MOU with General Motors. The most recent rating by Loop Capital, on November 20, 2020, is a Buy.
    Vaxart Inc. (VXRT) gained over 3.92% at $7.95 in pre-market trading Wednesday December 02, 2020.
    salesforce.com inc. (CRM) lost over -4.16% at $231.3 in pre-market trading Wednesday December 02, 2020 after introducing service cloud workforce engagement to help contact centers thrive in an all-digital, work-from-anywhere world.
    InVivo Therapeutics Holdings Corp. (NVIV), a Biotechnology company, rose about 2.42% at $0.635 in pre-market trading Wednesday.
    FuelCell Energy Inc. (FCEL) stock plunged -20.11% to $7.23 in the pre-market trading following the publication pricing of its underwritten public offering of 34,518,539 shares of its common stock, at a public offering price of $6.50 per share. The most recent rating by JP Morgan, on November 19, 2020, is a Neutral.
    Pershing Square Tontine Holdings Ltd. (PSTH), a Shell Companies company, rose about 2.34% at $26.25 in pre-market trading Wednesday.
    Virgin Galactic Holdings Inc. (NYSE: SPCE) shares are trading up 4.37% at $29.59 at the time of writing after reporting its new flight window since it paused the spaceflight preparations in response to state guidelines from the New Mexico Department of Health to reduce the spread of COVID-19. Company’s 52-week ranged between $7.14 to $42.49. Analysts have a consensus price target of $19.
    Second Sight Medical Products Inc. (EYES) stock moved down -8.0 percent to $1.38 in the pre-market trading.
    BioNTech SE (BNTX) grew over 7.36% at $122.4 in pre-market trading today after declaring that it will hold a press conference including a video webcast on Wednesday, December 2, 2020, to provide an update on the status of the COVID-19 vaccine development program of its lead vaccine candidate BNT162b2.
    Sogou Inc. (SOGO), a Internet Content & Information company, rose about 3.09% at $8.68 in pre-market trading Wednesday.
    Tellurian Inc. (TELL) is down more than -4.29% at $1.56 in pre-market hours Wednesday December 02, 2020 and the firm recently declared the appointment veteran CEO and adds industry experts to board of directors. The stock had jumped over 9.40% to $1.63 in the last trading session.
    Arlo Technologies Inc. (ARLO) lost over -3.48% at $6.66 in pre-market trading Wednesday December 02, 2020.
    Before the trading started on December 02, 2020, ZoomInfo Technologies Inc. (ZI) is down -3.57% to reach $46.22 as the firm announced pricing of secondary offering of shares of class a common stock. It has been trading in a 52-week range of $30.83 to $64.40.

  • Surge Continued For Stocks of Vaccine Makers -Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX) Rose On Monday

    Surge Continued For Stocks of Vaccine Makers -Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX) Rose On Monday

    Moderna Inc (MRNA) was up 20.24%on Monday at $152.74. The biotechnology company has therefore applied for marketing authorizations for its coronavirus vaccine in the United States and Europe, which has been shown to be more than 94% successful in advanced clinical trials.

    Pfizer Inc (PFE) gained 2.90 percent to $38.31 and BioNTech SE (BNTX) added 12.96 percent to close at $124.24 on Monday. The drug manufacturing companies were able to receive regulatory approvals in the United Kingdom and the United States for their 95 percent successful vaccine candidate within a few days.

    Novavax Inc (NVAX) saw a rise of 10.99 percent to conclude the trading at $139.50. Stock of soared, while the biotechnology company again postponed the launch in the United States of a Phase III clinical trial of its Covid experimental vaccine, but cited a possible start-up in the coming weeks.

    S&P Global Inc (SPGI) was up 2.99 percent to $351.78. As expected, it announced IHS Markit’s acquisition of $44 billion in shares, the biggest merger and value acquisition since the beginning of the year. The total capitalization of IHS Markit is $37 billion.

    Airbnb is looking for a $30 billion to $33 billion valuation for its Wall Street IPO. Food distribution player, DoorDash, with its more than tripled sales in nine months and first quarterly profit, is also greedy for its IPO with a cap from $25 billion to $28 billion. Both companies are planning to join the Wall Street in mid-December.

    Netflix Inc (NFLX) slipped -0.13 percent to $490.70 in the last session. The video streaming service is expected to begin disclosing revenue of more than GBP 1 billion from British subscribers to tax authorities in the UK, according to the Guardian. The Guardian claims that Netflix’s decision could place pressure on other U.S. tech giants such as Google or Amazon, who are currently preventing such reporting by optimizing their taxation.

  • BioNTech (NASDAQ: BNTX) And Pfizer Starts Rolling Submission For COVID-19 Vaccine Candidate

    BioNTech (NASDAQ: BNTX) And Pfizer Starts Rolling Submission For COVID-19 Vaccine Candidate

    BioNTech SE (NASDAQ: BNTX) and Pfizer, Inc. (NYSE: PFE) has announced today that they have started the rolling submission to the European Medicines Agency (EMA) to get approval for the COVID-19 vaccine candidate BNT162b2. European Medicines Agency (EMA) took the decision of review after seeing the promising preliminary results from pre-clinical and early clinical studies in adults.

    The preclinical study disclosed that BNT162b2 triggers the production of neutralizing antibodies and TH-1 dominant CD4+ and CD8+ T cells that target SARS-CoV-2, the virus which caused the COVID-19 disease. The study proved that the combination of antibody and T cell are important tools against the novel coronavirus.

    Pfizer and BioNTech have disclosed that they are planning to work closely with the EMA’s Committee for Medicinal Products for Human Use (CHMP) to finalize the rolling review process to enable the final Marketing Authorization Application (MAA). In rolling review, CHMP has started evaluating data generated in pre-clinical trials.

    The term “rolling review” means that the regulatory authority has begun evaluating the first batch of data on the vaccine. In the rolling review of BNT162b2, the European Medicines Agency (EMA) will evaluate the real-time data which the company gathered after giving doses to patients in different trials. Instead of submitting all that data at once, it is better to start the rolling review so that the company will be able to know where its vaccine candidate stands.

    Shares of BioNTech (NASDAQ: BNTX) traded up 6.49% as it gained +5.24 at $85.94 during the trading session of Tuesday. In the past 52-weeks of trading, this company’s stock has fluctuated between the low range of $12.52 and a high range of $105.00. It has moved up 586.15% from its 52-weeks low and moved down -18.15% from its 52-weeks high. This company market capitalization has remained high, hitting $18.96 billion at the time of writing.

    On the other hand, Pfizer Inc. (NYSE: PFE) shares were trading down 0.20% as it lost -0.08 during at the time of writing on Tuesday. Pfizer Inc. share price went from a low point around $27.88 to briefly over $ in p40.97ast 52 weeks, though shares have since pulled back to $36.67. PFE market cap has remained high, hitting $204.16 Billion at the time of writing.

    The BNT162b2 vaccine candidate is based on the proprietary mRNA technology of BioNTech. It is supported by Pfizer’s global vaccine development and manufacturing capabilities. BioNTech aimed to develop a potential vaccine at this period of uncertainty where COVID-19 is spreading all around the world.